Latest Conference Articles

Four-year follow-up data from the KEYNOTE-042 show promising survival and durable response in patients with non–small cell lung cancer.

Matthew J. Matasar, MD, discusses the ways to improve on the combination of R-CHOP in patients with diffuse large B-Cell lymphoma.

Evidence for on-target activity of temferon has been demonstrated in patients with glioblastoma, according to the phase 1/2a TEM-GBM study.

According to a phase 1/2 study, nivolumab plus PD-L1/IDO peptide vaccine may be effective for the treatment of patients with metastatic melanoma.

During a presentation, Paul G. Richardson, MD, talked about the shift from triplet combination therapies toward quadruplet combinations for the treatment of multiple myeloma.

Adam Cohen, MD, discusses his presentation on updates in BCMA-directed therapies for multiple myeloma, which he gave during the 3rd Summit of the Americas on Immunotherapies for Hematologic Malignancies.

Guenther Koehne, MD, PhD, discusses the exciting presentations going on at the 3rd Summit of the Americas on Immunotherapies for Hematologic Malignancies.

Lower rates of neutropenia and hypokalemia were also observed with maribavir than valganciclovir, ganciclovir, and foscarnet, and a lower proportion of HCT recipients discontinued treatment with maribavir than IAT.

Relatlimab plus nivolumab demonstrated reduction in risk of progression or death and numerically improved overall survival compared to nivolumab alone.

According to Primo Nery Lara, Jr, MD, frontline treatment options for metastatic renal cell carcinoma have been improving rapidly.

In recent years, the field of metastatic urothelial cancer has seen many new immunotherapy agents and targeted therapies that have improved patient outcomes.

Kevin Kalinsky, MD, MS, discussed selective estrogen receptor downregulators being explored for the treatment of breast cancer clinical trials.

Tailored treatment available to patients with HER2-positive metastatic breast cancer based on the presence of active central nervous system disease.

In the phase 3 monarchE clinical trial, long-term follow-up results show that the benefit of abemaciclib plus endocrine therapy continued beyond 2 years.

A team-oriented approach based on guideline-directed therapies should be used by clinicians to address patients experiencing cardiotoxicity as a result of their breast cancer, according Jean-Bernard Durand, MD.

Progress in the treatment of early-stage triple-negative breast cancer includes the now common use of neoadjuvant combinations of immunotherapy with chemotherapy.

Elacestrant demonstrates statistically significant and clinically meaningful improvement in progression-free survival for patients with ER–positive, HER2-negative mBC who previously received CDK4/6 inhibition.

According to real-world research, eribulin may be an effective treatment for patients with metastatic breast cancer who were previously treated with atezolizumab or sacituzumab govitecan.

Thromboembolic events and risk of progression continue to affect patients with polycythemia vera, but 2 recent advances may affect the natural course of the disease.

The future of myelofibrosis may include several JAK inhibitor treatment niches as well as combination regimens with JAK inhibition in both the upfront and second-line setting and more, according to John Mascarenhas, MD.

Steven M. Albelda, MD, discusses introduction of chimeric antigen receptor T-cell therapy in the solid tumor space.

“It's an exciting time with all the novel agent development in relapsed indolent lymphoma,” according to Brad S. Kahl, MD.

Even with the available agents and knowledge of when to select which option, there is an unmet medical need in the chronic lymphocytic leukemia landscape, according to Jennifer R. Brown, MD, PhD.

Lori A. Leslie, MD, discusses her recent presentation around chimeric antigen receptor T-cell therapy for mantle cell lymphoma and indolent lymphomas.

In a presentation Eytan M. Stein, MD, reported on single agent inhibitors followed by methods to overcome resistance using combination therapy.

Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma, and while many trials have failed to change the standard of care and improve outcomes, new opportunities for targeted treatment are growing, according to Brian T. Hill, MD, PhD.

The phase 2 PERICLES trial of atezolizumab with or without radiotherapy in patients with stage IV cancer did not meet its primary end point of 1-year progression-free survival.

Updated findings from the phase 3 KEYNOTE-564 trial may further support adjuvant pembrolizumab as a new standard of care for patients with renal cell carcinoma with high risk of recurrence.

NeoAvAx trial results show that neoadjuvant avelumab/axitinib may be beneficial to patients with renal cell carcinoma.

Health-related quality of life outcomes was more sustainable in patients with advanced renal cell carcinoma on nivolumab plus cabozantinib compared to sunitinib.